DexCom (NASDAQ:DXCM – Get Free Report) and Precision Optics (NASDAQ:POCI – Get Free Report) are both healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their analyst recommendations, profitability, risk, valuation, institutional ownership, dividends and earnings.
Valuation & Earnings
This table compares DexCom and Precision Optics”s top-line revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| DexCom | $4.66 billion | 6.67 | $836.30 million | $2.55 | 32.68 |
| Precision Optics | $31.53 million | 1.82 | -$3.63 million | ($0.46) | -11.37 |
DexCom has higher revenue and earnings than Precision Optics. Precision Optics is trading at a lower price-to-earnings ratio than DexCom, indicating that it is currently the more affordable of the two stocks.
Profitability
This table compares DexCom and Precision Optics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| DexCom | 19.42% | 37.77% | 15.98% |
| Precision Optics | -11.51% | -23.92% | -13.05% |
Institutional & Insider Ownership
97.8% of DexCom shares are owned by institutional investors. Comparatively, 13.7% of Precision Optics shares are owned by institutional investors. 0.3% of DexCom shares are owned by insiders. Comparatively, 12.7% of Precision Optics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.
Analyst Recommendations
This is a breakdown of recent ratings and target prices for DexCom and Precision Optics, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| DexCom | 0 | 2 | 24 | 2 | 3.00 |
| Precision Optics | 1 | 0 | 0 | 0 | 1.00 |
DexCom presently has a consensus target price of $95.50, indicating a potential upside of 14.60%. Given DexCom’s stronger consensus rating and higher probable upside, analysts plainly believe DexCom is more favorable than Precision Optics.
Volatility & Risk
DexCom has a beta of 1.45, meaning that its share price is 45% more volatile than the S&P 500. Comparatively, Precision Optics has a beta of 0.23, meaning that its share price is 77% less volatile than the S&P 500.
Summary
DexCom beats Precision Optics on 14 of the 15 factors compared between the two stocks.
About DexCom
DexCom, Inc. develops and markets continuous glucose monitoring (CGM) systems for people with diabetes. Its wearable sensors measure glucose levels throughout the day and send readings to compatible receivers or mobile devices, helping users monitor glucose trends and support treatment decisions. The company’s products include its Dexcom G6 and G7 CGM systems, along with software and connected services for users and caregivers. DexCom also offers Stelo, an over-the-counter glucose biosensor designed for adults who do not use insulin.
About Precision Optics
Precision Optics Corporation, Inc. designs and manufactures optical systems and components for medical, defense, aerospace and industrial applications. Its work spans product development, prototyping, engineering and production for customers seeking specialized imaging solutions. The company’s products include rigid and flexible endoscopes, three-dimensional endoscopic imaging systems, micro-optics and other precision optical assemblies. Its offerings support medical-device makers and other organizations that need compact, high-performance imaging equipment.
Receive News & Ratings for DexCom Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DexCom and related companies with MarketBeat.com's FREE daily email newsletter.
